Abstract:OBJECTIVE:To evaluate the therapeutic effect of mucosal tolerance on inflammatory bowel disease (IBD). METHODS:Forty-two SD rats underwent enema of 2, 4, 6-trinitro-benzene-sulfonic acid (TNBS) so as to establish models of experimental colitis and then divided into 7 equal groups: colitis group (without treatment), oral ovalbumin (OVA) group (undergoing gastric perfusion of OVA as inducing antigen), nasal OVA group (undergoing OVA nose dropping), oral OVA plus adjuvant group [undergoing gastric perfusion OVA with lipopolysaccharide (LPS) as adjuvant], nasal OVA plus adjuvant group, adjuvant control group, and blank control group (administrated with PBS orally). Another 6 rats were used as blank control group. All of the rats were executed 21 days after enema with their spleens taken out. Splenic lymphocytes were isolated and co-cultured with OVA for 96 h. MTT method was used to calculate the proliferation index so as to detect the mucosal tolerance. Macroscopical and histolopathological scores of colon were estimated so as to evaluate the therapeutic effects. RESULTS:Typical manifestations of colitis occurred 3-4 days after enema and persisted to the day 21 after enema. The macroscopical and histolopathological scores of colon of the colitis group (mean rank were 9.5 and 9.5) were both significantly higher than those of the normal control group (mean rank were 3.5 and 3.5 both P < 0.01). The splenic lymphocyte proliferation indexes of the oral OVA plus LPS, nasal OVA, and nasal OVA plus LPS groups were 0.11 +/- 0.05, 0.12 +/- 0.07, and 0.06 +/- 0.04 respectively, all significantly lower than that of the normal control group (0.30 +/- 0.13, all P < 0.05), however, without significant differences among these 3 groups (all P > 0.05). The splenic lymphocyte proliferation indexes of the oral OVA group was 0.25 +/- 0.10, not significantly different from that of the normal control group (P > 0.05). The macroscopical scores of the oral OVA plus LPS group, nasal OVA plus LPS group, and oral LPS alone group were 3.0 +/- 1.3, 2.0 +/- 0.6, and 4.3 +/- 1.0 respectively, all significantly lower than that of the colitis group (6.3 +/- 0.8, all P < 0.05); and the histological score of the oral OVA plus LPS group, nasal OVA plus LPS group, and oral LPS alone group were 3.0 +/- 1.1, 2.7 +/- 1.0, and 4.6 +/- 1.6 respectively, all significantly lower than that of the colitis group (7.5 +/- 1.0, all P < 0.05). The colonic score of the nasal OVA plus LPS group was most significantly decreased. CONCLUSION:Colitis interferes with the induction of oral tolerance, but not the induction of nasal tolerance. Both oral tolerance combined with adjuvant and nasal tolerance combined with adjuvant have therapeutic effects on experimental colitis. Oral adjuvant alone also has therapeutic effect on colitis, and the therapeutic effect of nasal tolerance combined with adjuvant is the best.

The protective effect of oral colitis-derived proteins in a murine model of inflammatory bowel disease is associated with an increase in γδ T cells in large intestinal mucosa

The Protective Effect Of Oral Colitis-Derived Proteins In A Murine Model Of Inflammatory Bowel Disease Is Associated With An Increase In Gamma Delta T Cells In Large Intestinal Mucosa

The effect of oral tolerance on the roles of small intestinal intraepithelial lymphocytes in murine colitis induced by dextran sodium sulfate

Changes of CD8⁺ T Cells in Dextran Sulfate Sodium-Induced Colitis Mice Pretreated with Oral Immune Regulation.

The Therapeutic Role of Oral Tolerance in Dextran Sulfate Sodium‐induced Colitis Via Th1–Th2 Balance and Γδ T Cells

Amelioration of Dextran Sulfate Sodium-Induced Experimental Ulcer Colitis in Mice by Bacillus licheniformis

Effects Of Appendectomy And Oral Tolerance On Dextran Sulfate Sodium Colitis

Dietary intervention with serum-derived bovine immunoglobulins protects barrier function in a mouse model of colitis

Protective Effect of Gallus gallus domesticlus Brisson Peptides on Dextran Sodium Sulfate-Induced Ulcerative Colitis in Mice

Low Dose of Cyanidin-3-O-Glucoside Alleviated Dextran Sulfate Sodium-Induced Colitis, Mediated by CD169+ Macrophage Pathway.

Alleviation Effects of Bifidobacterium animalis subsp. lactis XLTG11 on Dextran Sulfate Sodium-Induced Colitis in Mice

Ameloration of DSS-induced Acute and Chronic Colitis by GM-CSF

Bacteroides acidifaciens and its derived extracellular vesicles improve DSS-induced colitis

Glycated Casein by TGase-Type Exerts Protection Potential against DSS-Induced Colitis via Inhibiting TLR4/NF-κB Signaling Pathways in C57BL/6J Mice

Protective Effect of Saccharomyces Boulardii on Intestinal Mucosal Barrier of Dextran Sodium Sulfate-Induced Colitis in Mice

Peptidoglycan Recognition Proteins Protect Mice from Experimental Colitis by Promoting Normal Gut Flora and Preventing Induction of Interferon-γ

Oral Administration of Lactobacillus Paracasei Alleviates Clinical Symptoms of Colitis Induced by Dextran Sulphate Sodium Salt in BALB/c Mice.

[Therapeutic effects of mucosal tolerance on inflammatory bowel disease: experiment with rats].

Protective Effect of Tuna Bioactive Peptide on Dextran Sulfate Sodium-Induced Colitis in Mice

Upregulation of Intestinal Barrier Function in Mice with DSS-Induced Colitis by a Defined Bacterial Consortium Is Associated with Expansion of IL-17A Producing Gamma Delta T Cells

Elemental Diet Enriched with Amino Acids Alleviates Mucosal Inflammatory Response and Prevents Colonic Epithelial Barrier Dysfunction in Mice with DSS-Induced Chronic Colitis